Our mission is to develop life-changing therapeutics for people living with metabolic diseases including obesity and diabetes.
The novel incretin agonists we are developing arose out of our proprietary Chemotype Evolution platform. This platform enabled us to design a pipeline of incretin therapeutics intended to exhibit the appropriate balance of bias and desirable therapeutic attributes.
Carmot’s founders had a vision of leveraging Chemotype Evolution to discover life-changing therapeutics for people living with metabolic diseases.